Tweet ST. PAUL, MN, Aria CV today announced that it has completed a $31 million Series B round of financing to fund its first clinical study in the United States.

To export Aria CV funding data to PDF and Excel, clickClick here for more funding data on Aria CVTo export Aria CV funding data to PDF and Excel, click here Aria CV, a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that it has completed a $31 million Series B round of financing to fund its first clinical study in the United States.

The funding will support an Early Feasibility Investigational Study designed to evaluate long term implants of the Aria CV Pulmonary Hypertension System (Aria CV PH System) in PAH patients.

"Aria CV is now well positioned to drive our clinical research forward," said Dan Gladney, CEO and President of Aria CV.

About Aria CV, Inc.Based in St. Paul, Minnesota, Aria CV was founded in 2010 by Drs. | To read full story, visit https://startuparound.com/read/1582668012.378959/Aria-CV-Receives-$31M-Series-B-Funding?ref=audio_experience